Larry Kessler, Sc.D.

Dr. Kessler is Professor in the Department of Health Systems and Population Health, University of Washington, which he chaired from 2009 – 2015. He has over 40 years of experience in health services research, including positions at the National Institute of Mental Health, National Cancer Institute, and FDA. At NCI, he and his colleagues substantially […]

Kevin Elias

Dr. Kevin Elias is an experienced physician-scientist with a demonstrated history of success in translational medicine and advanced oncologic care. He has years of experience in Medical Education, Clinical Trials & Healthcare Leadership for gynecologic oncology and early cancer detection. Graduating from Harvard College and Vanderbilt University School of Medicine, he completed his residency in […]

Amy P.N. Skubitz, Ph.D.

Amy P.N. Skubitz, Ph.D. is a Professor in the Department of Laboratory Medicine and Pathology at the University of Minnesota (UM) and an Adjunct Professor in the Department of Obstetrics, Gynecology, and Women’s Health. Dr. Skubitz serves as the Director of the Ovarian Cancer Early Detection Program (OCEDP) at the UM. Her research interests include […]

Elizabeth Garner

Elizabeth Garner, MD, MPH has over a decade of pharmaceutical development experience. She also has deep expertise in clinical trial design and execution. She has held roles of increasing strategic responsibility in large and small companies, including ObsEva SA, Merck, Abbott (AbbVie), Myriad Genetics, and Agile Therapeutics. In addition to Pharm-Olam, she is also on […]

Surbhi Sarna

Surbhi Sarna is the founder and former CEO of nVision medical, a medical device company that, to date, is the only device cleared by the FDA to collect cells from the fallopian tube for the detection of ovarian cancer. Having led the company from inception, nVision Medical was acquired by Boston Scientific in 2018 for […]

Prof. Uri Saragovi, PhD

Dr. Saragovi is a passionate and world-leading scientist in the area of Translational Medicine. Dr. Saragovi has published over 200 publications and 21 patents, primarily focusing translational medicine. More recently Dr. Saragovi has focused on the targeting of gangliosides, which are used clinically for cancer diagnosis, prognosis, and therapy. Dr. Saragovi based at McGill University […]